Glenmark Pharma Share Price in Focus as US Arm Launches Olanzapine for Injection
- July 6, 2026
- Posted by: Kunal Singla
- Category: News
Glenmark Pharma share price CMP Rs 2,235, up 1.09%. US subsidiary launches Olanzapine for Injection 10 mg/vial, bioequivalent to Zyprexa IntraMuscular Injection.
Glenmark Pharma share price is in focus on 6 July 2026 after Glenmark Pharmaceuticals Inc., USA announced the launch of Olanzapine for Injection, 10 mg per vial, in a single dose vial format. The product is bioequivalent and therapeutically equivalent to the reference listed drug, Zyprexa IntraMuscular Injection 10 mg per vial, of Cheplapharm Registration GmbH.
The launch extends Glenmark’s expanding portfolio of generic injectable medicines in the United States, a segment the company has been building out steadily through a series of product launches over the past year.
Click Here – Get Free Investment Predictions
About Glenmark Pharmaceuticals
Glenmark Pharmaceuticals is a research led, global pharmaceutical company with a presence across branded, generics and OTC segments, focused on therapeutic areas including respiratory, dermatology and oncology, with 11 manufacturing facilities spread across four continents and operations in over 80 countries.
Why Glenmark Pharma Share Price Is in Focus Today
Glenmark Pharma share price is in focus because the Olanzapine for Injection launch adds to a steady cadence of generic injectable approvals and launches the company has delivered in the US market, an area of consistent portfolio expansion. Investors tracking Glenmark Pharma share price can view live quotes and fundamentals on the Univest stock page for Glenmark Pharmaceuticals before assessing the launch.
Details of the Olanzapine for Injection Launch
Glenmark’s Olanzapine for Injection, 10 mg per vial in a single dose vial format, is bioequivalent and therapeutically equivalent to Zyprexa IntraMuscular Injection, 10 mg per vial, of Cheplapharm Registration GmbH. Olanzapine injection is used in the acute treatment of agitation associated with schizophrenia and bipolar I mania, making it a hospital administered product typically used in emergency and inpatient psychiatric care settings.
Part of a Broader US Injectables Push
This launch continues a pattern of frequent generic injectable introductions by Glenmark’s US subsidiary, which has in recent months launched products including Lacosamide Injection, Vancomycin Hydrochloride for Injection, and various phosphate and bicarbonate injection formulations. This steady cadence of launches reflects the company’s strategy of building a broader, differentiated injectable product portfolio in the United States, a segment seeing increasing demand for hospital administered therapies.
Glenmark Pharma Share Price and Recent Performance
Glenmark Pharma share price was quoting at Rs 2,227.75, up Rs 17.90 or 0.81 percent, after touching an intraday high of Rs 2,247.70 and a low of Rs 2,220.75. Trading volumes stood at 8,670 shares compared to the five day average of 16,887 shares, a decrease of 48.66 percent. The company had reported a 6,381.9 percent surge in consolidated net profit to Rs 301.41 crore on a 16.8 percent increase in revenue in Q4 FY26, reflecting a strong recent earnings trajectory.
Talk to a SEBI Registered Investment Advisor on Univest
Glenmark Pharma US Launch Details
The table below summarises the key details of the Olanzapine for Injection launch.
| Detail | Value |
|---|---|
| Product | Olanzapine for Injection, 10 mg/vial |
| Format | Single-Dose Vial |
| Reference Drug | Zyprexa IntraMuscular Injection (Cheplapharm Registration GmbH) |
| Market | United States |
| Subsidiary | Glenmark Pharmaceuticals Inc., USA |
Download the Univest iOS App or Univest Android App to track Glenmark Pharma share price live and get daily pharma sector research.
What This Launch Means for Glenmark Pharma
Frequent generic injectable launches like this Olanzapine product typically add incremental revenue rather than transformative growth on their own, but collectively they demonstrate Glenmark’s disciplined execution in building a differentiated US generics portfolio. Investors tracking Glenmark Pharma share price should view this launch as part of a broader pattern of steady pipeline execution rather than a standalone catalyst, with the company’s overall US generics revenue trajectory being the more meaningful metric to watch.
Conclusion
Glenmark Pharma share price is in focus on 6 July 2026 after the company’s US subsidiary launched Olanzapine for Injection, bioequivalent to Zyprexa IntraMuscular Injection, extending its growing US injectables portfolio. The stock was trading around Rs 2,227.75 during the session. Track the company’s continued US launch cadence and consult a SEBI registered advisor before making any investment decision.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions on Glenmark Pharma Share Price
Why is Glenmark Pharma share price in focus today?
Ans. Glenmark Pharma share price is in focus because its US subsidiary, Glenmark Pharmaceuticals Inc., USA, launched Olanzapine for Injection, 10 mg per vial, bioequivalent to Zyprexa IntraMuscular Injection, extending its US injectables portfolio.
What is Glenmark’s Olanzapine for Injection used for?
Ans. Olanzapine for Injection is used in the acute treatment of agitation associated with schizophrenia and bipolar I mania, and is typically administered in hospital and emergency psychiatric care settings.
Which reference drug is Glenmark’s Olanzapine for Injection based on?
Ans. Glenmark’s Olanzapine for Injection is bioequivalent and therapeutically equivalent to Zyprexa IntraMuscular Injection, 10 mg per vial, of Cheplapharm Registration GmbH.
What was Glenmark Pharma share price on 6 July 2026?
Ans. Glenmark Pharma share price was quoting at Rs 2,227.75, up 0.81 percent, after touching an intraday high of Rs 2,247.70 and a low of Rs 2,220.75.
Has Glenmark launched other US injectables recently?
Ans. Yes. Glenmark’s US subsidiary has recently launched several other generic injectables including Lacosamide Injection and Vancomycin Hydrochloride for Injection, reflecting a steady cadence of US portfolio expansion.
Is Glenmark Pharma share price a buy after this product launch?
Ans. This article does not constitute investment advice. Individual generic launches typically add incremental rather than transformative revenue. Review the company’s overall US generics trajectory and consult a SEBI registered financial advisor before making any investment decision.
